Sheila Figel

Roswell Park Comprehensive Cancer Center

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma”.

Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Journal of Clinical Oncology(2022)10.1200/jco.22.00996

N/A

2.3DataRank · unranked

159 citations

David A. Reardon, Ajay Abad, William T. Curry, Eric T. Wong, Sheila Figel +15 more

Wild type, dEX3 and 2B survivin isoforms localize to the tumor cell plasma membrane, are secreted in exosomes, and interact with extracellular tubulin

Biochemistry and Biophysics Reports(2021)10.1016/j.bbrep.2021.101174

N/A

0.330DataRank · unranked

8 citations

Meaghan Birkemeier, Sanam Dharma, Tara A. Barone, Emma Steinmetz, Michael J. Ciesielski +2 more

Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM

Cancer Immunology Immunotherapy(2025)10.1007/s00262-025-04193-y

N/A

0DataRank · unranked

2 citations

Sheila Figel, Jingxin Qiu, Manmeet S. Ahluwalia, David Reardon, Ajay Abad +8 more